Chen Jonathan J, Schmucker Lyndsey N, Visco Donald P
Dept. of Biology, The University of Akron, 302 Buchtel Common, Akron, OH, 44325.
Dept. of Chemical and Biomolecular Engineering, The University of Akron, 302 Buchtel Common, Akron, OH, 44325.
Biotechnol Prog. 2018 Nov;34(6):1553-1565. doi: 10.1002/btpr.2693. Epub 2018 Sep 27.
Blood Clotting Factor XI is an important actor in the clotting mechanism: it activates downstream zymogen involved in the clotting process. It can be targeted for activation or inhibition depending on treatment goals to enhance or inhibit clotting. In terms of antithrombosis treatment, Factor XI has emerged as a promising target to focus on. In this work, an iterative virtual high-throughput screening pipeline was proposed that can supplement current efforts to find inhibitors. The first iteration identified 11 compounds to test with 3 active for a hit-rate of 27.3%. The second iteration of the pipeline identified another 11 compounds to test with 7 active for a hit-rate of 63.6%. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:1553-1565, 2018.
凝血因子XI是凝血机制中的一个重要因子：它激活参与凝血过程的下游酶原。根据增强或抑制凝血的治疗目标，可以对其进行激活或抑制。在抗血栓治疗方面，因子XI已成为一个有前景的关注靶点。在这项工作中，提出了一种迭代虚拟高通量筛选流程，该流程可以补充当前寻找抑制剂的工作。第一轮迭代鉴定出11种化合物进行测试，其中3种具有活性，命中率为27.3%。该流程的第二轮迭代又鉴定出11种化合物进行测试，其中7种具有活性，命中率为63.6%。© 2018美国化学工程师学会 生物技术进展，34:1553 - 1565，2018年。
